Premium
Nucleus‐Targeted Organoiridium–Albumin Conjugate for Photodynamic Cancer Therapy
Author(s) -
Zhang Pingyu,
Huang Huaiyi,
Banerjee Samya,
Clarkson Guy J.,
Ge Chen,
Imberti Cinzia,
Sadler Peter J.
Publication year - 2019
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201813002
Subject(s) - photodynamic therapy , photosensitizer , human serum albumin , chemistry , cytotoxicity , conjugate , cancer cell , biophysics , albumin , maleimide , serum albumin , spheroid , phototoxicity , in vitro , cancer research , cancer , photochemistry , biochemistry , medicine , biology , polymer chemistry , organic chemistry , mathematical analysis , mathematics
An organoiridium–albumin bioconjugate ( Ir1‐HSA ) was synthesized by reaction of a pendant maleimide ligand with human serum albumin. The phosphorescence of Ir1‐HSA was enhanced significantly compared to parent complex Ir1 . The long phosphorescence lifetime and high 1 O 2 quantum yield of Ir1‐HSA are highly favorable properties for photodynamic therapy. Ir1‐HSA mainly accumulated in the nucleus of living cancer cells and showed remarkable photocytotoxicity against a range of cancer cell lines and tumor spheroids (light IC 50 ; 0.8–5 μ m , photo‐cytotoxicity index PI=40–60), while remaining non‐toxic to normal cells and normal cell spheroids, even after photo‐irradiation. This nucleus‐targeting organoiridium‐albumin is a strong candidate photosensitizer for anticancer photodynamic therapy.